Genetically engineered mouse models of ovarian cancer and their utility in drug discovery

Sanja Sale1

  • 1Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.

Insights

Developing accurate mouse models for ovarian cancer (EOC) is vital for understanding disease progression and finding new treatments. This study presents two novel methods for transforming ovarian surface epithelial cells in genetically engineered mouse models (GEMMs).

Area of Science:

  • Oncology
  • Genetics
  • Gynecologic Oncology

Background:

  • Ovarian cancer (EOC) is a leading cause of death in women due to late detection and drug resistance.
  • Most EOCs originate from ovarian surface epithelia (OSE).
  • Accurate in vivo models are needed to study EOC pathogenesis and develop therapies.

Purpose of the Study:

  • To describe novel methods for transforming OSE cells in genetically engineered mouse models (GEMMs).
  • To facilitate the development of EOC GEMMs that accurately mimic human disease.
  • To explore applications of these models in oncology drug discovery.

Main Methods:

  • Two distinct methods for transforming OSE cells in GEMMs are detailed.
  • Focus on achieving tissue-specific transgene expression in adult OSE cells.
  • Leveraging recent advancements in gene delivery technology.

Main Results:

  • Successful transformation of OSE cells in GEMMs using the described methods.
  • Establishment of novel GEMMs for EOC research.
  • Demonstration of the utility of these models for drug discovery.

Conclusions:

  • The presented methods overcome historical challenges in EOC GEMM development.
  • These advanced GEMMs offer powerful tools for understanding EOC initiation and progression.
  • Applications in oncology drug discovery and development are significant.